Most lumps on the eyelid are harmless: a chalazion, a stye or a benign skin growth. But a pearly bump that bleeds and crusts, a spot where the lashes have fallen out, or a "chalazion" that keeps returning in the same place can be an eyelid cancer, and found early it is highly curable. This guide to eyelid cancer treatment in Turkey (Türkiye) and elsewhere covers the warning signs, the main types, and how tumors are removed and the eyelid rebuilt: the point where eye cancer care and eyelid surgery meet.
What is eyelid cancer?
Eyelid cancers start in the skin of the lid or in its small glands, and most are linked to years of sun exposure. The cell a tumor comes from determines how it behaves and how it is treated.
| Type | Share of eyelid cancers | Typical appearance | Behavior |
|---|---|---|---|
| Basal cell carcinoma | about 80–90% | pearly nodule with fine surface vessels, sometimes a central ulcer | grows slowly; almost never spreads to distant organs |
| Squamous cell carcinoma | about 5–10% | scaly, crusted or ulcerated patch or lump | can spread to lymph nodes and along nerves |
| Sebaceous gland carcinoma | about 3% in one Western series | firm yellowish lump, or one-sided "blepharitis" | imitates benign conditions; can spread over the eye surface |
| Merkel cell carcinoma | rare | fast-growing red-purple nodule | aggressive; often reaches lymph nodes |
| Melanoma | about 1% | brown or black patch or lump with irregular edges | risk depends mainly on thickness |
Is it a harmless lump or eyelid cancer?
Benign lesions are far more common: chalazia (blocked oil glands), seborrheic keratoses, skin tags, moles, small cysts and yellow cholesterol plaques called xanthelasma. Features that raise suspicion of cancer include:
- lost eyelashes over a lump, or a notched lid margin;
- a sore that bleeds, crusts or ulcerates and does not heal;
- a pearly, rolled edge with tiny visible blood vessels;
- a firm nodule that keeps growing or feels fixed to deeper tissue;
- a "chalazion" that returns in the same place or does not respond to treatment;
- persistent one-sided "blepharitis" in an older adult, or numbness of the lid or forehead.
Who is at risk of eyelid cancer?
The main risk factor is years of ultraviolet (UV) exposure, especially in fair skin and after decades outdoors in strong sunshine. Older age, radiotherapy to the face, a weakened immune system (for example after an organ transplant), previous skin cancers and rare inherited syndromes also raise the risk.
What are the main types of eyelid cancer?
Basal cell carcinoma of the eyelid
Basal cell carcinoma (BCC) favors the lower lid and the inner corner. The nodular form is a shiny bump with fine vessels and sometimes a central crater; the infiltrative form is flat and scar-like and spreads further under the skin than it appears, so it recurs more often. BCC almost never spreads to distant organs. The danger is local destruction and, if neglected, invasion of the eye socket.
Squamous cell carcinoma
Squamous cell carcinoma (SCC) is less common but more aggressive. It often arises on sun-damaged skin, sometimes from a precancerous patch (actinic keratosis), and can spread to the lymph nodes in front of the ear and under the jaw or creep along nerves, causing numbness, double vision or a drooping lid. Long-term immune-suppressing treatment markedly raises the risk.
Sebaceous carcinoma of the eyelid: the "great masquerader"
This cancer arises from the oil glands of the lid, mostly the meibomian glands in the firm tarsal plate; the upper lid, which has about twice as many of these glands, is affected more often. It is more common in women, with a median age at diagnosis of 57 to 72 in published series, and is reported to be relatively more frequent in parts of South and East Asia.
It convincingly imitates a chalazion or one-sided blepharitis, so diagnosis is often delayed. It can also spread in a thin layer across the conjunctiva and resemble other conjunctival tumors, which is why several small "map" biopsies are taken.
Sebaceous carcinoma can signal Muir–Torre syndrome, a variant of Lynch syndrome linked to bowel and other internal cancers, so tumor testing, genetic counseling and colonoscopy may be advised. In a meta-analysis of 1,333 patients, metastasis occurred in about 12%, local recurrence in about 16% and death from the tumor in about 6%.
Merkel cell carcinoma
This rare neuroendocrine skin cancer affects older or immunosuppressed people; about 80% of cases are linked to Merkel cell polyomavirus. On the eyelid it appears as a red-violet nodule near the upper lid margin that does not hurt but enlarges over weeks. Up to 37% of patients already have lymph node involvement at diagnosis, so surgery is usually combined with radiotherapy.
Eyelid melanoma
Melanoma causes about 1% of eyelid cancers, most often as lentigo maligna: a slowly spreading brown patch on sun-damaged skin that can extend onto the eye surface (see conjunctival melanoma). It is staged like skin melanoma, mainly by thickness. Published recurrence rates were 0–3.6% after Mohs-type surgery with special stains, compared with 6–20% after standard excision.
How is eyelid cancer diagnosed?
The specialist examines the lid under the slit lamp, turns it over, feels the lymph nodes in front of the ear and in the neck, and photographs the lesion. A biopsy confirms the diagnosis: part of the lesion (incisional biopsy) or, if it is small, all of it (excisional biopsy) is examined by a pathologist. Suspected sebaceous carcinoma needs a full-thickness sample plus conjunctival map biopsies.
Scans are added for large, recurrent or fixed tumors, restricted eye movement, a bulging eye or numbness: contrast MRI shows spread along nerves and CT shows bone. Some higher-risk tumors also need a sentinel lymph node biopsy (see how eye tumors are diagnosed). For a second opinion, send dated photographs, the pathology report and the original scan files.
How is eyelid cancer staged?
Basal cell, squamous cell and sebaceous carcinomas of the eyelid use the AJCC 8th edition (TNM 8) system; melanoma and Merkel cell carcinoma follow the skin cancer systems.
| Category | Meaning |
|---|---|
| Tis | carcinoma in situ, confined to the surface layer |
| T1 | tumor 10 mm or smaller |
| T2 | larger than 10 mm and up to 20 mm |
| T3 | larger than 20 mm and up to 30 mm |
| T4 | invades the eye, orbit, face, bone, sinuses, tear drainage system or brain |
| N / M | spread to lymph nodes (N1–N2) or distant organs (M1) |
T1 to T3 are subdivided by depth, from "a" (lid margin and tarsal plate spared) to "c" (full thickness). See eye cancer stages.
Eyelid cancer treatment: removing the tumor with margin control
Surgery is the mainstay. Its goal is a clear margin, meaning healthy tissue all around and beneath the tumor, while keeping a lid that closes and protects the eye. Standard "bread-loaf" slicing of a specimen examines less than 1–2% of the margin, so eyelid tumor removal relies on methods that check the whole edge, known as complete circumferential peripheral and deep margin assessment (CCPDMA).
| Approach | How the margins are checked | Typical use |
|---|---|---|
| Mohs micrographic surgery | thin layers removed; each whole edge and base checked on frozen sections the same day | basal and squamous cell carcinoma, especially infiltrative, recurrent or inner-corner tumors |
| Excision with frozen-section control | edges checked by a pathologist during the operation | many basal and squamous cell carcinomas |
| Staged excision with complete margin assessment (CCPDMA, "slow Mohs") | whole edge and base checked on processed (permanent) sections; repair a day or more later | melanoma and sebaceous carcinoma at many centers |
| Radiotherapy, creams or freezing | no margin check | people unfit for surgery, selected superficial lesions |
Mohs surgery, done by a trained Mohs surgeon, usually clears a tumor in one or two stages while sparing healthy tissue; an oculoplastic surgeon often rebuilds the lid the same or the next day. In a randomized trial of primary facial basal cell carcinoma, recurrence at 30 months was 3% after standard excision and 2% after Mohs surgery, and about 18% of first standard excisions were incomplete.
Surgery also outperformed radiotherapy for basal cell carcinoma (4-year failure 0.7% versus 7.5%). Radiotherapy remains valuable when surgery is not possible, and after surgery for nerve or lymph node involvement, positive margins or Merkel cell carcinoma.
How is the eyelid rebuilt after the tumor is removed?
An eyelid has a front layer (skin and muscle) and a back layer (tarsal plate and conjunctiva). Eyelid reconstruction replaces what was removed; if one layer is a free graft, the other must bring its own blood supply as a flap. The aims are full closure, a stable lid margin, working tear drainage and a natural look.
| Size of the defect | Common repair |
|---|---|
| up to about a quarter to a third of the lid length | edges stitched directly together |
| up to about half | direct closure after releasing the tendon at the outer corner |
| about half to three-quarters | rotation flap from the outer corner (Tenzel flap) |
| larger, lower lid | two-stage Hughes flap from the upper lid, or a cheek rotation flap |
| larger, upper lid | two-stage Cutler–Beard flap from the lower lid, or a graft plus a flap |
In two-stage repairs the lids are joined and the eye stays closed until a short second operation divides the flap: usually after a few weeks for a Hughes flap and after 6–8 weeks for a Cutler–Beard flap. They are avoided where possible in young children (risk of lazy eye) and in people with only one seeing eye. Grafts come from the other upper lid, skin near the ear, or the lining of the mouth. See also eyelid surgery.
What if the eyelid cancer is advanced?
When a tumor invades the eye socket, bone or sinuses, or clearing it would mean removing the eye, a multidisciplinary team decides the treatment. The medicines below are supervised by medical oncologists, and their availability differs between countries.
- Hedgehog pathway inhibitors (vismodegib, sonidegib) are daily tablets for advanced basal cell carcinoma. In trials, about 43–60% of locally advanced tumors responded to vismodegib and about 42% to sonidegib. Muscle cramps, hair loss and taste changes are common, about 3 in 10 patients stop because of side effects, and the drugs must not be used in pregnancy.
- Immunotherapy with PD-1 or PD-L1 inhibitors: cemiplimab treats advanced cutaneous squamous cell carcinoma, and basal cell carcinoma after hedgehog inhibitors. On 8 October 2025 the U.S. FDA approved cemiplimab as adjuvant therapy for high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy; in the 415-patient C-POST trial it lowered the risk of recurrence or death by about two-thirds versus placebo. Cosibelimab (Unloxcyt), approved in December 2024 for squamous cell carcinoma that surgery or radiation cannot cure, produced responses in about 47–48% of patients.
- Radiotherapy or, as a last resort, orbital exenteration (removal of the eye and socket contents): see enucleation, exenteration and the artificial eye and orbital tumors.
What are the outcomes, and how often are check-ups needed?
- Basal cell carcinoma: 5-year cure rates reach about 98%, lower for tumors over 3 cm and for long-neglected or recurrent tumors.
- Merkel cell carcinoma: 5-year survival was 97% with cancer-free lymph nodes and 52% with involved nodes.
- Melanoma: 10-year survival ranges from up to 93% for stage IA to 10–15% for stage IV.
| Tumor | Typical follow-up |
|---|---|
| Basal cell carcinoma | eyelid and skin check every 6–12 months for at least 5 years |
| Squamous cell, sebaceous and Merkel cell carcinoma, melanoma | every 3–6 months for 2–3 years, with lymph node checks, then every 6–12 months |
Daily sun protection and periodic whole-skin checks are part of long-term care. Our article Is eye cancer curable? puts these figures in context.
Eyelid cancer treatment in Turkey: care with Prof. Türkoğlu in Antalya
Prof. Türkoğlu is a Professor of Ophthalmology and ocular oncologist with more than 20 years in ophthalmology; her academic career was at the Akdeniz University Faculty of Medicine in Antalya. She also has an oculoplastic background: she began her specialist career in the oculoplastic unit of Sakarya University Training and Research Hospital and is a member of the American and European oculoplastic societies (ASOPRS, ESOPRS).
She examines the lesion, performs the biopsy, plans the excision and margin control with the pathologist, and reconstructs the eyelid. Where Mohs surgery, radiotherapy or systemic drugs are needed, they are delivered together with the relevant specialist teams.
Patients abroad can start by sending photographs and pathology reports. A small excision with immediate repair needs a stay long enough for the check-up and stitch removal; staged repairs need a second short operation weeks later. See eye tumor surgery and international patients.
Frequently asked questions
Is a lump on my eyelid likely to be cancer?
Most eyelid lumps are benign: chalazia, cysts, moles or seborrheic keratoses. Cancer becomes more likely when a lump bleeds or ulcerates, has made eyelashes fall out, distorts the lid margin, keeps growing or returns after treatment. Any lesion with these features should be examined by an eye specialist and usually biopsied.
Can a chalazion be cancer?
A true chalazion is a blocked oil gland and is not cancer. However, sebaceous carcinoma can look almost exactly like one. A "chalazion" that keeps returning in the same place, or does not respond to the usual treatment, should be biopsied and the tissue examined by a pathologist.
Can eyelid cancer spread to the eye or the brain?
Neglected or aggressive tumors, especially at the inner corner or those that travel along nerves, can grow into the eye socket and, rarely, beyond it. Early, complete removal prevents this in the great majority of cases. Numbness, double vision or a bulging eye alongside an eyelid tumor needs prompt imaging.
Do I need Mohs surgery?
Not necessarily. Mohs surgery and excision with frozen-section control both check the margins closely; the choice depends on the tumor type, size and location, and the expertise available. For melanoma and sebaceous carcinoma, many centers prefer complete margin assessment on permanent sections before the eyelid is rebuilt.
Will my eyelid look different after surgery?
Reconstruction aims for a lid that closes, protects the eye and looks natural. Small defects are closed directly, leaving a fine scar; larger ones need flaps and grafts, sometimes in two stages with the eye closed for a few weeks. Some asymmetry or a short lash-free segment can remain.
Are there tablets or injections instead of surgery?
For advanced basal cell carcinoma, hedgehog inhibitor tablets can shrink tumors; for advanced squamous cell and Merkel cell carcinoma, immunotherapy is used. These treatments can sometimes spare the eye, but they have side effects and are given with medical oncologists. For most early tumors, surgery remains the most reliable cure.
References
- American Academy of Ophthalmology. Basal Cell Carcinoma. EyeWiki. eyewiki.org
- American Academy of Ophthalmology. Sebaceous Carcinoma. EyeWiki. eyewiki.org
- American Academy of Ophthalmology. Merkel Cell Carcinoma. EyeWiki. eyewiki.org
- American Academy of Ophthalmology. Malignant Melanoma of the Eyelid. EyeWiki. eyewiki.org
- American Academy of Ophthalmology. Targeted Therapies for Periocular Malignancies. EyeWiki. eyewiki.org
- NHS National Disease Registration Service. [TNM 8 staging sheet: carcinoma of the skin of the eyelid]. digital.nhs.uk
- American Academy of Ophthalmology. Mohs Micrographic Surgery. EyeWiki. eyewiki.org
- National Cancer Institute. [Skin cancer treatment: PDQ summary for health professionals, updated May 2025]. cancer.gov
- American Academy of Ophthalmology. Eyelid Reconstruction. EyeWiki. eyewiki.org
- American Academy of Ophthalmology. Hughes Procedure. EyeWiki. eyewiki.org
- U.S. Food and Drug Administration. [Approval of cemiplimab-rwlc as adjuvant treatment for cutaneous squamous cell carcinoma, 8 October 2025]. fda.gov
- U.S. Food and Drug Administration. [Approval of cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma, 13 December 2024]. fda.gov